a study on Hepatitis B
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase.
A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase
Hepatitis B, Chronic Interferons Interferon-alpha Lamivudine Peginterferon alfa-2a Entecavir
Open to people ages 3 years to 17 years
Detectable HBV-DNA (>20,000 IU/mL) as measured by polymerization chain reaction (PCR)or hybridization on at least 2 occasions at least one month apart with the latest determination obtained less than or equal to (=) 42 days prior to baseline
Either Liver biopsy performed within 2 years prior to baseline showing no or minimal fibrosis (Liver Biopsy Scores and stable normal ALT levels (less than or equal to upper limit of normal [ULN]) during the 6 months leading up to baseline (including two separate occasions at least 1 month apart over the 6 months prior to baseline).Screening ALT levels must be normal (= ULN) OR Stable normal ALT levels (= ULN),during the 1 year leading up to baseline (including three separate occasions at least 1 month apart over the 1 year prior to baseline) and no signs of hepatocellular carcinoma (HCC), advanced fibrosis/cirrhosis, or splenomegaly on liver abdominal ultrasound at screening. Screening ALT levels must be normal (= ULN)
HBV activity (Exception: Participants who have had a limited [= 7-day] course of acyclovir for herpetic lesions more than 1 month before the study baseline visit are not excluded)
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02263079.
© 2017 The Regents of the University of California